Vardenafil 5 mg is a strength used in U.S. labeling for film-coated oral tablets treating erectile dysfunction. It is part of the conventional tablet family rather than the distinct 10 mg orally disintegrating formulation. A tablet’s strength describes the amount of active ingredient in that product; it does not alone predict clinical response or a patient’s appropriate prescription.
The FDA-approved product identity matters as much as the number printed on a pharmacy label. Different generic labelers may have distinct appearance and imprint descriptions. An approved application or label does not establish that a particular pharmacy currently has that product ready for pickup. In some U.S. product labels, 5 mg has specific starting-dose relevance for older adults and moderate hepatic impairment, though other interactions can demand different limits.
This page focuses on recognizing the 5 mg presentation and its labeled ED context. The strengths directory compares all conventional strengths, while the dosage page explains the prescriber-controlled factors behind a regimen.
The labeled 5 mg presentation is a conventional oral film-coated vardenafil hydrochloride tablet. The drug is a PDE5 inhibitor used for erectile dysfunction, and sexual stimulation is required for a response. It is not an over-the-counter supplement or a treatment that can be selected solely from an online strength chart.
Product specifications, including shape, color and imprint, are manufacturer-dependent. A pharmacist can identify an actual supplied generic using its labeling instead of assuming that photographs of the old Levitra brand correspond to the dispensed tablet.
Five milligrams is not only a generic 'lower option' in conventional vardenafil labeling. U.S. labels advise considering 5 mg as an initial dose in patients aged 65 years or older. For moderate hepatic impairment (Child-Pugh B), labeling recommends a 5 mg initial dose and limits the maximum to 10 mg. These are clinician-facing restrictions, not grounds for age-based or liver-related self-prescribing.
Some potent metabolic inhibitors impose still lower dosing ceilings or longer intervals, so a 5 mg product is not automatically acceptable with every other medicine. Original U.S. Levitra 5 mg branding was discontinued; approved generic status and current dispensing supply must be checked separately. The Levitra history page explains the former brand.
When comparing prescriptions, the dosage form is easy to overlook. A complete review ties the numerical strength to the actual approved tablet and the pharmacist’s directions.
The same checklist applies whether the medicine is collected locally or dispensed by a licensed online pharmacy.
| Check | What to look for | Why it matters |
|---|---|---|
| Active ingredient | Vardenafil hydrochloride | Confirms the named medicine |
| Product type | Film-coated oral tablet | Separates it from ODT |
| Strength | 5 mg on the dispensing label | Matches the prescribed presentation |
| Applicant or labeler | Specific approved product identity | Avoids relying on brand imagery |
| Quantity and directions | Exact prescription instructions | Prevents self-directed changes |
| Current supply | Pharmacist confirmation | Approval does not guarantee inventory |
Conventional vardenafil tablets are prescribed for as-needed use in relation to sexual activity. Label-based timing and frequency details apply to the specific product, but an individual’s regimen may require adjustment based on medication history or other conditions.
Food and interactions can affect the discussion, and a timing instruction should not be interpreted as a guaranteed onset. The administration guide distinguishes practical use from dose selection.
Nitrates and riociguat are contraindicated with vardenafil. Its QT-prolongation caution also matters for patients with relevant cardiac histories or who use certain antiarrhythmics; blood-pressure medicines and CYP3A4 inhibitors can influence medical decisions.
Five milligrams is not always within an applicable interaction-specific limit: certain vardenafil film-coated labels restrict ritonavir or cobicistat coadministration to no more than 2.5 mg in 72 hours. These examples are reasons for a prescriber or pharmacist to check the exact current label rather than to halve or combine tablets independently. The interaction guide covers other medicines.
The current and historical ODT products involve a 10 mg dissolving form with different exposure characteristics. It is not appropriate to infer that any arithmetic combination of film-coated tablets will reproduce an ODT product or vice versa.
Pharmacists should verify the exact formula and prescription whenever dosage-form substitution is proposed. Staxyn history describes the original branded dissolving product, while the ODT guide addresses current generic labeling.
FDA records can establish that a generic product was approved and that its labeling includes a 5 mg tablet. They cannot show whether a particular pharmacy will have it available during a planned visit.
Ask about the exact approved product and stock before traveling or paying for delivery. If there is a shortage at a pharmacy, it should coordinate a lawful alternative with the prescriber rather than instructing a patient to improvise a dose.
A quote should identify the 5 mg film-coated generic, prescribed count, payment method and all dispensing or delivery charges. An advertisement for a different strength, discontinued brand or ODT formulation is not directly comparable.
For cost factors rather than stale numbers, see the vardenafil price guide. For questions about actual stock, use the availability page.
Check the container for active ingredient, labeled 5 mg strength, correct form and directions. Ask the pharmacist if an unfamiliar appearance results from a different approved labeler. Confirm any restrictions and interactions that the clinician has discussed.
If serious symptoms occur, such as chest pain or fainting, seek emergency assessment and tell the care team about recent vardenafil use. An erection lasting more than four hours also requires emergency evaluation.
Yes. The 5 mg strength appears in U.S. labeling for conventional film-coated vardenafil hydrochloride tablets.
No. U.S. film-coated tablet labeling discusses 5 mg as a possible starting strength for adults 65 and older and for moderate hepatic impairment, but other conditions and interacting medicines may make even 5 mg inappropriate. A clinician must select the regimen.
No. Staxyn was a distinct 10 mg orally disintegrating formulation with different pharmacokinetic labeling.
Specific generic film-coated vardenafil products with this labeled strength have FDA records; verify the actual dispensed application and labeling.
No. Vardenafil must not be combined with nitrates or riociguat regardless of tablet strength.
A licensed pharmacist can assess legally permitted substitution for the exact form and strength; do not independently change the prescription.
No. Current inventory needs to be checked directly with the pharmacy.
No. Online strength charts do not replace an individualized prescribing decision.